Skip to main content

Table 4 Characteristics of eligible trials for Ewing sarcoma only

From: Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

Author Year Intervention Phase No of Patients Outcome
Hawkins et al, Med Pediatric Oncol, 34 (5): 328-37 [33] 2000 Myeloablative therapy followed by HSCT. I 16 3-year EFS 36%
Kolb et al, J Clin Oncol, 21 (18): 3423-30 [75] 2003 7 cycles of chemotherapy consisted of Cyclo, Doxo, Vin, Ifos and Etop II 68 29 (43%) CR, 13 (19%) PD or SD
Meyer et al, Sarcoma, 7 (1): 13-7 [76] 2003 Doc thrice weekly for a maximum of six cycles. II 14 1 (14%) PR, 2 (28%) SD
Bernstein et al, J Clin Oncol, 24 (1): 152-9 [77] 2006 High-dose induction therapy followed by window period. Randomization between topo, topo + cyclo or no treatment. No window treatment patients received Amifostine II 117 45 (43%) CR, 41 (39%) PR, 14 (14%) SD
Womer et al, ASCO abstract 2008 Vin, Doxo and Cyclo alternating with Ifos and Etop, for 14 cycles. Regimen A: 3 weeks cycle, regimen B: 2 week cycle. Primary tumor treatment was scheduled to begin week 13. II 587 EFS at a median of 3 years was 65% in Regimen A and 76% in Regimen B.
Rosenthal et al, Bone Marrow Transplantation, 42: 311-8 [78] 2008 HDT followed by HSCT. I 22 3-year EFS 47%, 3-year OS 45%
DuBois et al, Pediatric Blood Cancer, 52 (3): 324-7 [79] 2009 Cytarabine. II 10 1 (10%) SD
Casey et al, Pediatric Blood Cancer, 53 (6): 1029-34 [80] 2009 Irinotecan and Temozolomide. II 20 5 (25%) CR, 7 (36%) PR
Olmos et al, Lancet Oncol, 11: 129-35 [56] 2010 A subgroup of Ewing Sarcoma patients were treated with Figitumumab I 15 1 (6%) CR, 1 (6%) PR, 6 (37%) SD
  1. Abbreviations: CR = complete response; Cyclo = cyclophosphamide; Doc = docetaxel; Doxo = doxorubucine; EFS = event free survival; Etop = etoposide; G-CSF = granulocyte-colony stimulating factor; HDT = high-dose chemotherapy; HSCT = hematopoietic stem cell transplantation; Ifos = ifosfamide; OR = overall response; OS = overall survival; PD = progressive disease; PR = partial response; SD = stabile disease; Topo = topotecan; Vin = vincristine